Results 111 to 120 of about 8,463 (257)

Combined neurokinin-1 receptor antagonist and sorafenib is a promising approach for hepatocellular carcinoma therapy

Egyptian Liver Journal
Background HCC (Hepatocellular carcinoma) is the most common primary malignant cancer in the liver. Treatment options to incurable HCC such as sorafenib, an oral multikinase inhibitor, had numerous side effects and questionable effectiveness.
Heba E. Sedky, Yasmine N. Elwany, Eman S. El Alfy, Mona N. Elwany, Yasmin M. Nabil, Hazem F. Manna, Mohamed A. Abdelaziz, Wessam F. El Hadidy   +7 more
doaj   +1 more source

Pilot Study of Aprepitant for Prevention of Post-ERCP Pancreatitis in High Risk Patients: A Phase II Randomized, Double-Blind Placebo Controlled Trial

, 2012
Tilak Shah, Rodger A. Liddle, M. Stanley Branch, Paul S. Jowell, Jorge Obando, Martin Poleski   +5 more
openalex   +1 more source

P1.03-20 The Novel SFN Inhibitors Aprepitant and Ticagrelor Exert Anti-Tumor Effects Through Blocking of Oncoprotein Ubiquitination [PDF]

, 2018
Aya Shiba, Jinsheng Hong, Takatsugu Hirokawa, Y. Kim, Masayuki Noguchi   +4 more
openalex   +1 more source

EVALUASI PENGGUNAAN ANTIEMETIKA PADA PASIEN KANKER NASOFARING DENGAN KEMOTERAPI DI INSTALASI RAWAT INAP RSUD Dr MOEWARDI SURAKARTA TAHUN 200 [PDF]

, 2010
Penggunaan obat kemoterapi dapat menyebabkan mual dan muntah, obat kemoterapi pada kanker nasofaring merupakan obat dengan emetogenisitas tinggi dan sedang. Efek ini dapat menurunkan efektivitas penggunaan kemoterapi bila tidak ditangani dengan tepat.
RAHAYU , PRIYANTI
core  

Tratamiento de la emesis inducida por citotóxicos [PDF]

, 2004
Nausea and vomiting are important side effects of most chemotherapy anticancer drugs, since nearly two thirds of the patients under chemotherapy have this toxicity in absence of antiemetic treatment.
López, Sara, Martín, Miguel
core   +1 more source

Eficacia del aprepitant para la prevención de la náusea y el vómito postoperatorios. Revisión sistemática y metaanálisis de ensayos clínicos

, 2014
Marta Inés Berrío Valencia, Juan Pablo Botero Aguirre   +1 more
openalex   +2 more sources

Guideline for the Treatment of Breakthrough and the Prevention of Refractory Chemotherapy-induced Nausea and Vomiting in Children with Cancer [PDF]

, 2016
Basch, Bauters, Bodge, Chanthawong, Choi, Choo, Dupuis, Dupuis, Dupuis, Dupuis, Flank, Flank, Gardani, Gore, Guyatt, Guyatt, Hachimi-Idrissi, Hesketh, Higi, Kaiser, Kang, Massa, McCabe, Musso, Navari, Sanofi-Aventis Canada Inc, Schnell, Shillingburg, Shiu, Smith, Smith, Wit   +31 more
core   +1 more source

The efficacy of single dose palonosetron in highly emetogenic chemotherapy protocols compared to oral aprepitant and ondansetron

, 2022
Yaala Saady Raof Al-Bairmany, Noor Kasib Hadi, Abdul Karim Nazar   +2 more
openalex   +1 more source

Aprepitant in refractory pruritus of systemic lymphoproliferative disorders

, 2020
A. Pulido‐Pérez, Fernando Carretero‐López, Marta Bergón‐Sendín, Lula María Nieto‐Benito, Rosa Romero‐Jiménez, Nieves Dorado‐Herrero, Mariana Bastos‐Oreiro, R. Suárez‐Fernández   +7 more
openalex   +2 more sources

The efficacy of combination of ondansetron and aprepitant on preventing the radiotherapy-induced nausea and vomiting

Journal of Research in Medical Sciences, 2015
Background: Depending on the site of irradiation, about 40-80% of patients undergoing radiotherapy (RT) will experience nausea and/or vomiting. The current study aimed to investigate the efficacy of ondansetronas as a single agent and with a combination ...
Hamid Emami, Simin Hematti, Seyed Masoud Saeidian, Awat Feizi, Shahin Taheri, Pourya Adeli, Golshan Mahmoudi   +6 more
doaj